12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivantinib: Additional Phase II data

Additional data from a subgroup of 37 patients with high c-Met expression as measured by immunohistochemistry in a double-blind, international Phase II trial showed that twice-daily oral tivantinib produced median OS of 7.2 months vs. 3.8 months for placebo (p=0.01). The trial enrolled 107 patients with unresectable HCC who failed 1 prior systemic therapy. Patients initially received placebo or twice-daily 360 mg...

Read the full 288 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >